InsiderSignal.AI

InsiderSignal.ai

MNKD - Mannkind Corp

Insider Purchase by Castagna Michael (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Castagna Michael, serving as CEO at Mannkind Corp (MNKD), purchased 100,000 shares at $2.59 per share, for a total transaction value of $259,000.00. Following this transaction, Castagna Michael now holds 2,577,411 shares of MNKD.

This purchase represents a 4.00% increase in Castagna Michael's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 10, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 10, 2026, meaning the disclosure happened on the same day as the trade.

Mannkind Corp operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Castagna Michael

Castagna Michael

CEO

Michael E. Castagna, Pharm.D., MBA, is the Chief Executive Officer and a member of the Board of Directors at MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company, since May 2017. He joined the company in March 2016 as Chief Commercial Officer. Age 48, Castagna holds a pharmacy degree from the University of the Sciences, a Pharm.D. from Massachusetts College of Pharmacy & Sciences, and an MBA from the Wharton School.[[1]](https://fintool.com/app/research/companies/MNKD/people/michael-castagna)[[2]](https://www.latimes.com/b2b/business-visionaries/c-suite/michael-castagna)[[3]](https://mannkindcorp.com/about/) With over 25 years of experience in healthcare, pharmaceuticals, and biotechnology, Castagna previously served as Vice President of Global Lifecycle Management and Global Commercial Lead for the Biosimilar Business Unit at Amgen (2012–2016), Executive Director of Immunology at Bristol-Myers Squibb (2010–2012 and earlier roles 1997–2005), Vice President & Head of Biopharmaceuticals, North America at Sandoz, and Director roles at Merck, Serono, and Pharmasset. Under his leadership, MannKind achieved significant growth, with 2024 revenue of $285.5 million, net income of $27.6 million, and strong total shareholder return (TSR), turning a $100 investment in 2019 into $498.45 by year-end 2024.[[1]](https://fintool.com/app/research/companies/MNKD/people/michael-castagna)[[2]](https://www.latimes.com/b2b/business-visionaries/c-suite/michael-castagna)[[3]](https://mannkindcorp.com/about/)[[5]](https://www.foxbusiness.com/markets/an-interview-with-mannkind-ceo-michael-castagna)

View full insider profile →

Trade Price

$2.59

Quantity

100,000

Total Value

$259,000.00

Shares Owned

2,577,411

Trade Date

Tuesday, March 10, 2026

6 days ago

SEC Filing Date

Tuesday, March 10, 2026

HEALTHCAREBIOTECHNOLOGY

About Mannkind Corp

Company Overview

No company information available
View news mentioning MNKD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4672551

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime